ArticleBMC cancer2026
High Ki-67 as an independent prognostic factor in extraskeletal osteosarcoma: a comparative cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objectives of this study are to compare clinicopathological features and outcomes of extraskeletal osteosarcoma (EOS) and conventional osteosarcoma (COS) and identify independent prognostic factors for disease-free survival (DFS) and overall survival (OS).
methodsThis study included 72 patients (Group EOS, n = 12; Group COS, n = 60) with a definitive diagnosis. Clinicopathological variables, SATB2 expression, and Ki-67 proliferation index were compared between groups. Outcomes were assessed using the Kaplan-Meier method and the log-rank test, and independent prognostic factors were identified by Cox regression analysis.
resultsGroup EOS had significantly higher median age (53.5 vs. 33.4 years, p < 0.001) and Ki-67 proliferation index than Group COS. Primary tumor location differed significantly (p < 0.001), with EOS cases affecting internal organs (kidneys, lungs) and COS cases mainly in long bones around the knee. Metastases were more common in Group EOS (83.3% vs. 13.6%, p < 0.001). Median OS and DFS for Group EOS were 19.3 months (vs. 71.6 months for COS, p = 0.007) and 2.2 months (vs. 21.6 months for COS, p < 0.001), respectively. Multivariate analysis identified age (OS: HR per year 1.04, 95% CI: 1.02-1.06, p < 0.001; DFS: HR 1.03, 95% CI: 1.02-1.05, p < 0.001) and Ki-67 proliferation index (OS: HR per %-point 1.02, 95% CI: 1.00-1.04, p = 0.038; DFS: HR 1.02, 95% CI: 1.01-1.04, p = 0.006) as independent prognostic factors.
conclusionsSurvival outcomes for patients with EOS were significantly worse than for those with COS. High Ki-67 proliferation index and advanced age were associated with a more aggressive clinical course of EOS. Therefore, more intensive follow-up and treatment are prudent for elderly EOS patients with a high Ki-67 proliferation index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.